Sale of shares in Renalytix AI plc

EKF Diagnostics Holdings

26/11/2020 07:00

RNS Number : 5458G

EKF Diagnostics Holdings PLC

26 November 2020

 

 

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Sale of shares in Renalytix AI plc

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has sold 1,675,000 ordinary shares in Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) at a price of £4.60 per ordinary share, in response to strong institutional demand. The sale has resulted in gross proceeds of £7.705m to EKF and generated a profit of over £5.6m after dealing expenses.

 

Following this transaction EKF will continue to hold 1,002,981 ordinary shares in Renalytix AI plc.

 

 

 

EKF Diagnostics Holdings plc
www.ekfdiagnostics.com
Christopher Mills, Non-executive Chairman
Tel: +44 (0) 29 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer
Tel: 020 7496 3000
Aubrey Powell / George Tzimas (Corporate Finance)
 Tom Salvesen (Corporate Broking)
Walbrook PR Limited
Tel: +44 (0) 20 7933 8780 orekf@walbrookpr.com
Paul McManus / Lianne Cawthorne
Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303


 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
MSCFELLLBFLLFBD